Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | glucose-6-phosphate 1-dehydrogenase | 0.0102 | 1 | 1 |
Trypanosoma brucei | glucose-6-phosphate 1-dehydrogenase | 0.0093 | 0.884 | 1 |
Trichomonas vaginalis | glucosamine-6-phosphate isomerase, putative | 0.0102 | 1 | 0.5 |
Trypanosoma cruzi | glucose-6-phosphate 1-dehydrogenase, putative | 0.0031 | 0.0125 | 0.0142 |
Plasmodium vivax | glucose-6-phosphate 1-dehydrogenase, putative | 0.0102 | 1 | 1 |
Treponema pallidum | glucose-6-phosphate 1-dehydrogenase | 0.0093 | 0.884 | 0.5 |
Echinococcus multilocularis | glucose 6 phosphate 1 dehydrogenase | 0.0093 | 0.884 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0048 | 0.2554 | 0.2535 |
Trichomonas vaginalis | glucosamine-6-phosphate isomerase, putative | 0.0102 | 1 | 0.5 |
Toxoplasma gondii | glucose-6-phosphate 1-dehydrogenase | 0.0061 | 0.4319 | 0.1724 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0048 | 0.2554 | 0.2535 |
Chlamydia trachomatis | glucose-6-phosphate 1-dehydrogenase | 0.0093 | 0.884 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0048 | 0.2554 | 0.2535 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0053 | 0.3135 | 0.3547 |
Brugia malayi | hypothetical protein | 0.0034 | 0.0538 | 0.0141 |
Echinococcus granulosus | glucose 6 phosphate 1 dehydrogenase | 0.0093 | 0.884 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0053 | 0.3135 | 0.3547 |
Mycobacterium tuberculosis | Probable glucose-6-phosphate 1-dehydrogenase Zwf2 (G6PD) | 0.0032 | 0.0328 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.2554 | 0.2535 |
Plasmodium falciparum | glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | 0.0102 | 1 | 1 |
Trypanosoma cruzi | glucose-6-phosphate 1-dehydrogenase, putative | 0.0093 | 0.884 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.3135 | 0.3226 |
Mycobacterium ulcerans | glucose-6-phosphate 1-dehydrogenase | 0.0093 | 0.884 | 1 |
Trichomonas vaginalis | 6-phosphogluconolactonase, putative | 0.0102 | 1 | 0.5 |
Loa Loa (eye worm) | glucose-6-phosphate dehydrogenase | 0.0093 | 0.884 | 1 |
Brugia malayi | hypothetical protein | 0.0053 | 0.3135 | 0.3226 |
Leishmania major | glucose-6-phosphate 1-dehydrogenase, putative | 0.0093 | 0.884 | 1 |
Schistosoma mansoni | glucose-6-phosphate 1-dehydrogenase | 0.0093 | 0.884 | 1 |
Brugia malayi | glucose-6-phosphate dehydrogenase | 0.0093 | 0.884 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.